SOD1 and amyotrophic lateral sclerosis: Whilst the therapeutic benefits of CuATSM, ebselen and telbivudine monotherapies, as well as CuATSM and ebselen polytherapy, have been demonstrated to rescue SOD1 toxicity in cell and mouse models of SOD1-associated ALS, the potential of a polytherapy incorporating all three compounds together has yet to be investigated.